
(AGENPARL) – SILVER SPRING mar 20 giugno 2023 Product approval information is indicated for children and adults with hemophilia B (congenital Factor IX deficiency) for 1) On-demand control and prevention of bleeding episodes; 2) Perioperative management of bleeding; 3) Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
Fonte/Source: http://www.fda.gov/vaccines-blood-biologics/approved-blood-products/idelvion